ViRexx to Present Hepatitis C Vaccine Data at HepDART 2005.EDMONTON, Alberta -- ViRexx Medical Corp. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension :VIR VIR Virtual VIR Virgin Islands (ISO Country code) VIR Virginia International Raceway VIR Vascular and Interventional Radiology VIR Vehicle Inspection Report VIR Virtual Interface (Alteon) ) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis Chronic hepatitis Long lasting inflammation of the liver due to viruses or other causes. Mentioned in: Tube Compression of the Esophagus and Stomach chronic hepatitis B & C and embolotherapy treatments for tumors, announced that an abstract relating to pre-clinical data from a hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. Chimigen(TM) vaccine candidate will be presented at the HepDART 2005: Frontiers in Drug Development for Viral Hepatitis viral hepatitis n. Any of various forms of hepatitis caused by a virus. viral hepatitis, n an inflammatory condition of the liver, caused by the hepatitis viruses: A, B, C, delta, E, F, G, or H. in Hawaii. The conference is being held from December 11 to December 15 in the Kohala Coast, Hawaii at the Fairmont Orchid Hotel. Dr. Lorne Tyrrell, Chief Executive Officer and Dr. Rajan George, Vice President, Research and Development, Infectious Diseases at ViRexx Medical Corp. will be presenting an abstract entitled "A Novel Dendritic dendritic /den·drit·ic/ (den-drit´ik) 1. branched like a tree. 2. pertaining to or possessing dendrites. den·drit·ic adj. Relating to the dendrites of nerve cells. Cell-Targeted Chimeric chi·mer·ic adj. 1. Relating to a chimera. 2. Composed of parts of different origin. Therapeutic Vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for the Treatment of Chronic C Infection". "The Chimigen(TM) technology targets patients with chronic hepatitis B or hepatitis C. It is estimated that 170 million people worldwide suffer from chronic hepatitis C. The poster presentation reviews pre-clinical data from a hepatitis C vaccine," said Dr. Lorne Tyrrell, Chief Executive Officer of ViRexx. "As part of our ongoing clinical development program, we recently filed a Clinical Trial Application to initiate a Phase I hepatitis B Chimigen(TM) vaccine trial and intend to select a vaccine candidate for clinical development for hepatitis C." About ViRexx Medical Corp. ViRexx is an Edmonton, Alberta based biotechnology company focused on the development of novel therapeutic products for the treatment of certain cancers and specified chronic viral infections. ViRexx's most advanced programs include drug candidates for the treatment of ovarian cancer, chronic hepatitis B and C and solid tumors. ViRexx's lead product, OvaRex(R) MAb, a therapy for the treatment of late-stage ovarian cancer, is currently the subject of two Phase III clinical trials being funded by ViRexx's licensing partner Unither Pharmaceuticals, Inc., a subsidiary of United Therapeutics Corporation. For additional information about ViRexx, please see www.virexx.com. This news release contains certain forward-looking statements that reflect the current views and/or expectations of the Company with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX has not approved or disapproved of the information contain ed herein. ViRexx Medical Corp. (TSX:VIR) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion